​

Adaptive Bio (ADPT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ADPT Stock Forecast

Adaptive Bio (ADPT) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $31.58, with a high of $35.00 and a low of $27.00. This represents a 23.79% increase from the last price of $25.51.

$10 $15 $20 $25 $30 $35 High: $35 Avg: $31.58 Low: $27 Last Closed Price: $25.51

ADPT Stock Rating

Adaptive Bio stock's rating consensus is Buy, based on 17 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (64.71%), 4 Hold (23.53%), 2 Sell (11.76%), and 0 Strong Sell (0.00%).

Buy
Total 17 0 2 4 11 Strong Sell Sell Hold Buy Strong Buy

ADPT Price Target Upside V Benchmarks

TypeNameUpside
StockAdaptive Bio23.79%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts3814
Avg Price Target$31.33$29.94$26.18
Last Closing Price$25.51$25.51$25.51
Upside/Downside22.81%17.37%2.63%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26261--9
Sep, 26251--8
Aug, 26251--8
Jul, 26251--8
Jun, 26251--8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 12, 2026Morgan Stanley$27.00$25.665.22%5.84%
Oct 01, 2026Guggenheim$32.00$28.6611.65%25.44%
Sep 29, 2026Evie KosloskyGoldman Sachs$35.00$28.5122.76%37.20%
Sep 22, 2026National Bank$34.00$27.8622.04%33.28%
Sep 21, 2026BTIG$34.00$27.8622.04%33.28%
Aug 04, 2026Piper Sandler$27.50$23.1119.00%7.80%
Jul 30, 2026Guggenheim$25.00$22.5610.82%-2.00%
Jul 30, 2026Mark MassaroBTIG$25.00$22.5610.82%-2.00%
Jul 09, 2026Morgan Stanley$20.00$20.16-0.79%-21.60%
Jun 29, 2026Guggenheim$22.00$20.964.96%-13.76%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 13, 2026Cowen & Co.BuyBuyhold
Oct 01, 2026GuggenheimBuyBuyhold
Sep 29, 2026Goldman SachsBuyinitialise
Sep 22, 2026BTIGBuyBuyhold
Aug 04, 2026Piper SandlerOverweightOverweighthold
Jul 30, 2026GuggenheimBuyBuyhold
Jul 30, 2026BTIGBuyBuyhold
Jul 15, 2026Cowen & Co.BuyBuyhold
Jun 29, 2026GuggenheimBuyBuyhold
Jun 17, 2026BTIGBuyBuyhold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-1.46$-1.00$-1.56$-1.08$-0.39-
Avg Forecast$-1.49$-1.47$-1.41$-1.12$-0.94$-0.67
High Forecast$-1.40$-1.41$-1.40$-1.11$-0.83$-0.52
Low Forecast$-1.56$-1.53$-1.44$-1.12$-1.03$-0.89
Surprise %-2.01%-31.97%10.64%-3.57%-58.51%-

Revenue Forecast

$100M $140M $180M $220M $260M $300M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$154.34M$185.31M$170.28M$178.96M$276.98M-
Avg Forecast$152.83M$185.10M$172.93M$177.62M$210.66M$264.13M
High Forecast$158.09M$190.53M$183.72M$179.32M$216.88M$265.49M
Low Forecast$145.20M$179.67M$168.57M$174.90M$204.25M$262.77M
Surprise %0.99%0.11%-1.54%0.75%31.48%-

Net Income Forecast

$-350M $-290M $-230M $-170M $-110M $-50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-207.28M$-200.19M$-225.25M$-159.49M$-59.50M-
Avg Forecast$-232.25M$-258.20M$-225.25M$-160.99M$-141.48M$-100.85M
High Forecast$-185.80M$-206.56M$-180.20M$-159.55M$-120.32M$-74.91M
Low Forecast$-278.70M$-309.84M$-270.30M$-162.43M$-148.21M$-128.21M
Surprise %-10.75%-22.47%--0.93%-57.94%-

ADPT Forecast FAQ

Is Adaptive Bio stock a buy?

Adaptive Bio stock has a consensus rating of Buy, based on 17 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 4 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Adaptive Bio is a favorable investment for most analysts.

What is Adaptive Bio's price target?

Adaptive Bio's price target, set by 17 Wall Street analysts, averages $31.58 over the next 12 months. The price target range spans from $27 at the low end to $35 at the high end, suggesting a potential 23.79% change from the previous closing price of $25.51.

How does Adaptive Bio stock forecast compare to its benchmarks?

Adaptive Bio's stock forecast shows a 23.79% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Adaptive Bio over the past three months?

  • October 2026: 22.22% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 25.00% Strong Buy, 62.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 25.00% Strong Buy, 62.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.

What is Adaptive Bio’s EPS forecast?

Adaptive Bio's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.67, marking a 71.79% increase from the reported $-0.39 in 2025..

What is Adaptive Bio’s revenue forecast?

Adaptive Bio's average annual revenue forecast for its fiscal year ending in December 2026 is $264.13M, reflecting a -4.64% decrease from the reported $276.98M in 2025.

What is Adaptive Bio’s net income forecast?

Adaptive Bio's net income forecast for the fiscal year ending in December 2026 stands at $-101M, representing an 69.50% increase from the reported $-59.499M in 2025.